Fraunhofer Institute for Cell Therapy and Immunology IZI

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute‘s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharma­ceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products within the business fields cell and gene therapy, drugs and vaccines, molecular diagnostics and immunodiagnostics, as well as extracorporeal therapies. Its areas of competence lie in cell biology, immunology, drug biochemistry, bioanalytics and bioproduction as well as process development and automation. Research in these areas is centered around developments in immuno-oncology and infectious disease pathology. The S3 safety laboratory allows research and development activities to be conducted and highly pathogenic agents investigated under biosafety level 3 conditions.

The institute works in close cooperation with hospital institutions and performs quality tests besides manufacturing investigational medicinal products in line with GMP requirements. Furthermore, it supports partners in developing processes for the pharmaceutical production of ATMPs and biologicals, for example by helping them to obtain manufacturing licenses.

News

Latest press releases

6.9.2022

Roadmap for future production of sufficient product numbers of cell-based cancer drugs

Cell-based immunotherapies, such as CAR T cell therapy, are effective means of treating cancer. However, technological advances in various disciplines are needed to meet the rapidly growing demand for such novel drugs. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology now summarize the current state of research and discuss possible solutions to overcome biological and technical hurdles in their recent article "Potential solutions for manufacture of CAR T cells in cancer immunotherapy" published in the journal Nature Communications.
Read more

5.9.2022

REMEDi4ALL, an ambitious EU-funded research initiative, launches to drive forward the repurposing of medicines in Europe

The EU-funded project REMEDi4ALL willl make a major leap forward in drug repurposing, or finding new therapeutic option for existing drugs, in areas where there are high unmet medical needs. The 3 Fraunhofer institutes participating, for Translational Medicine and Pharmacology ITMP, for Cell Therapy and Immunology IZI and for Algorithms and Scientific Computing SCAI, combine expertise in the realization of in-silico and in-vitro driven drug repurposing programs, the design of predictive in vivo models, the execution of clinical trials and algorithm development for the analysis of drug discovery data.
Read more

7.6.2022

Preclinical testing of a ATMP for the treatment of knee cartilage damage completed

The Fraunhofer Institute for Cell Therapy and Immunology IZI is certified as a GLP test facility. Most recently, the institute conducted, among other things, a preclinical study to test the safety of an ATMP for the treatment of cartilage damage to the knee. An advanced therapy medicinal product (ATMP) developed by BioPlanta GmbH was subjected to extensive testing under GLP conditions with regard to its potential undesirable biodistribution and tumorigenicity.
Read more

2.6.2022

Fraunhofer develops automated production technologies for mRNA-based drugs

Coordinated by the Fraunhofer Institute for Cell Therapy and Immunology IZI, seven Fraunhofer institutes are working on the development of automated production technologies for mRNA-based drugs. RNAuto is a Fraunhofer lighthouse project that will receive €8 million in funding from the Fraunhofer-Gesellschaft over the next four years.
Read more

Press / media

 

As an institution of application-oriented research, the Fraunhofer Institute for Cell Therapy and Immunology IZI attaches great importance to informing customers and the public.

Events

 

The Fraunhofer IZI offers its partners and guests space for communication.

Utilize our modern and representative premises for your event. The generously proportioned and modern space offered at the Institute provides space for, e. g., workshops, symposia, conferences and lectures.

 

 

Fraunhofer Prize for “Human- and Environment-Centered Technology” 2021

For a vaccine production process that is faster, more efficient and more environmentally friendly.

 

November 22–23, 2022 | Virtual conference

Leipzig Immune ONcology Conference (LION)

The LION Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology.

 

Fraunhofer lighthouse project

Automated production technologies for mRNA-based drugs

 

Saxon future cluster

SaxoCell

 

Annual report 2021/22

The annual report gives you an insight into the structure of the Fraunhofer IZI, our services, important events and publications, offers, as well as selected project examples.

Research projects funded by the EU

Research projects at Fraunhofer IZI that are supported by the Land of Saxony / Saxony-Anhalt / Mecklenburg-Western Pomerania using funds provided by the European Regional Development Fund (ERDF).

 

Business units and core competencies

The Fraunhofer IZI offers R&D services for pharmaceutical, biotechnological and medical technology companies as well as for partners from research institutions, hospitals and diagnostic laboratories.

Jobs / career

We keep you informed on current job offers at the Fraunhofer IZI. Find out about the possibilities the Fraunhofer-Gesellschaft could offer you as an employer.

Publications

We gladly provide our clients and partners as well as the interested public with information on our research activities.

 

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000

 

Social Media